<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Acta Naturae</journal-id><journal-title-group><journal-title xml:lang="en">Acta Naturae</journal-title><trans-title-group xml:lang="ru"><trans-title>Acta Naturae</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-8251</issn><publisher><publisher-name xml:lang="en">Acta Naturae Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">10400</article-id><article-id pub-id-type="doi">10.32607/20758251-2017-9-1-52-55</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Research Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Экспериментальные статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Prolyl-glycyl-proline (PGP) Peptide Prevents an Increase in Vascular Permeability in Inflammation</article-title><trans-title-group xml:lang="ru"><trans-title>Пептид пролил-глицил-пролин (PGP) препятствует повышению проницаемости кровеносных сосудов при воспалении</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Bondarenko</surname><given-names>N. S.</given-names></name><name xml:lang="ru"><surname>Бондаренко</surname><given-names>Н. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>n.s.bondarenko@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Shneiderman</surname><given-names>A. N.</given-names></name><name xml:lang="ru"><surname>Шнейдерман</surname><given-names>A. Н.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>n.s.bondarenko@gmail.com</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Guseva</surname><given-names>A. A.</given-names></name><name xml:lang="ru"><surname>Гусева</surname><given-names>A. A.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>n.s.bondarenko@gmail.com</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Umarova</surname><given-names>B. A.</given-names></name><name xml:lang="ru"><surname>Умарова</surname><given-names>Б. A.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>n.s.bondarenko@gmail.com</email><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Koltsov Institute of Developmental Biology</institution></aff><aff><institution xml:lang="ru">Институт биологии развития им. Н.К. Кольцова РАН</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Institute of Carcinogenesis, Cancer Research Center of N.N. Blokhin</institution></aff><aff><institution xml:lang="ru">НИИ канцерогенеза Российского онкологического научного центра им. Н.Н. Блохина</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Lomonosov Moscow State University</institution></aff><aff><institution xml:lang="ru">Московский государственный университет им. М.В. Ломоносова</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2017-03-15" publication-format="electronic"><day>15</day><month>03</month><year>2017</year></pub-date><volume>9</volume><issue>1</issue><issue-title xml:lang="en">VOL 9, NO1 (2017)</issue-title><issue-title xml:lang="ru">ТОМ 9, №1 (2017)</issue-title><fpage>52</fpage><lpage>55</lpage><history><date date-type="received" iso-8601-date="2020-01-17"><day>17</day><month>01</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2017, Bondarenko N.S., Shneiderman A.N., Guseva A.A., Umarova B.A.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2017, Бондаренко Н.С., Шнейдерман A.Н., Гусева A.A., Умарова Б.A.</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="en">Bondarenko N.S., Shneiderman A.N., Guseva A.A., Umarova B.A.</copyright-holder><copyright-holder xml:lang="ru">Бондаренко Н.С., Шнейдерман A.Н., Гусева A.A., Умарова Б.A.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://actanaturae.ru/2075-8251/article/view/10400">https://actanaturae.ru/2075-8251/article/view/10400</self-uri><abstract xml:lang="en"><p>This study was aimed at investigating the effect of prolyl-glycyl-proline (PGP) tripeptide on vascular permeability in rats with an inflammation. It was found that the peptide reduces the rat paw edema induced by a subcutaneous administration of histamine to the same extent as the conventional anti-inflammatory agent diclofenac. However, an assessment of the relative expression level of the cox-2 gene at the inflammation focus using real-time PCR showed that, in contrast to diclofenac, PGP does not affect the cox-2 gene expression. This is indicative of the fact that they have different mechanisms of action. We used the model of acute peritonitis induced by an intraperitoneal injection of thioglycolate to demonstrate that the inflammatory response of an organism is accompanied by increased vascular permeability in the tissues of the stomach and small intestine. Pre-administration (30 minutes before the induction of the inflammation) of PGP prevented this increase, whereby the level of vascular permeability, exudate volume in the peritoneal cavity, and the amount of the Evans Blue dye in this exudate remained at the control level. Therefore, these results suggest that the anti-inflammatory action of PGP is based on its ability to prevent an increase in vascular permeability.</p></abstract><trans-abstract xml:lang="ru"><p>Изучено влияние трипептида пролил-глицил-пролина (PGP) на проницаемость кровеносных сосудов крыс в условиях воспаления. Установлено, что пептид уменьшает отек лапы крыс, вызванный подкожным введением гистамина, в той же степени, что и классический противовоспалительный препарат диклофенак. Однако определение относительного уровня экспрессии гена cox-2 в очаге воспаления с помощью ПЦР в реальном времени показало, что, в отличие от диклофенака, PGP не влиял на экспрессию гена cox-2. Это свидетельствует о различии механизмов их действия. На экспериментальной модели острого перитонита, вызванного внутрибрюшинной инъекцией тиогликолата, показано, что воспалительная реакция сопровождается повышением проницаемости сосудов в тканях желудка и тонкого кишечника. Предварительное (за 30 мин до индукции воспаления) введение PGP предотвращало это повышение, вследствие чего проницаемость сосудов, объем экссудата в перитонеальной полости и количество красителя Evans Blue в нем оставались на уровне контрольных значений. Таким образом, полученные нами результаты свидетельствуют, что в основе противовоспалительного действия PGP лежит его способность предотвращать повышение проницаемости кровеносных сосудов.</p></trans-abstract><kwd-group xml:lang="en"><kwd>anti-inflammatory action</kwd><kwd>inflammation</kwd><kwd>prolyl-glycyl-proline (PGP)</kwd><kwd>vascular permeability</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>пролил-глицил-пролин (PGP)</kwd><kwd>воспаление</kwd><kwd>проницаемость сосудов</kwd><kwd>противовоспалительное действие</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>[1] Ashmarin I.P., Karazeeva E.P., LA Lyapina L.A., Samonina G.E. // Biochemistry (Mosc). 1998, V.63, №2, P.119-124</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>[2] Ashmarin I.P., Samonina G.E., Badmaeva K.E., Bakaeva Z.V., Vas’kovskii B.V., Zolotarev Iu.A. // Uspekhi fiziologicheskikh nauk. 2006, V.37, №2, P.11-18</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>[3] Bakaeva Z.V., Samonina G.E., Umarova B.A., Kopylova G.N., Goncharova E.L., Baglikova K.E. // Cytokines and inflammation. 2008, V.7, №2, P.28-32</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>[4] Umarova B.A., Lelekova T.V., Kopylova G.N., Samonina G.E., Bakaeva Z.V., Goncharova E.L., Bondarenko N.S. // Cytokines and inflammation. 2009, V.8, №3, P.44-47</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>[5] Umarova B.A., Bondarenko N. S., Kopylova G. N., Samonina G. E. // Biochemistry (Moscow) supplement series A: membrane and cell biology. 2011, V.5, №3, P.237-241</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>[6] Kumar P., Shen Q., Pivetti C.D., Lee E.S., Wu M.H., Yuan S.Y. // Expert reviews in molecular medicine. 2009, V.11, P.e19</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>[7] Kunder C.A., St John A.L., Abraham S.N. // Blood. 2011, V.118, №20, P.5383-5393</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>[8] Bakaeva Z.V., Badmaeva K.E., Sergeev I.Yu., Samonina G.E. // Bulletin of experimental biology and medicine. 2003, V.135, №4, P.334-336</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>[9] Bondarenko N.S., Kovalenko S.S., Kopylova G.N., Umarova B.A., Graevskaya E.E., Maksimov G.V. // Biologicheskie Membrany. 2013, V.30, №3, P.199-205</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>[10] Andreeva L.A., Mezentseva M.V., Nagaev I.Y., Shapoval I.M., Shcherbenko V.E., Potapova L.A., Russu L.I., Narovlyansky A.N., Ershov F.I., Myasoedov N.F. // Doklady biological sciences. 2010, V.434, P.300-303</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>[11] Haddox J.L., Pfister R. R., Sommers C. I., Blalock J. E., Villain M. // Investigative ophthalmology &amp; visual science. 1999, V.40, №10, P.2427-2429</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>[12] Kim S. D., Lee H. Y., Shim J. W., Kim H. J., Yoo Y. H., Park J. S., Bae I.O., Y.-S. I.O. // American journal of respiratory and critical care medicine. 2011, V.184, №2, P.243-251</mixed-citation></ref></ref-list></back></article>
